Cochrane Abstracts
Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone‐sensitive prostate cancer
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Abiraterone Acetate in Combination With Androgen Deprivation Therapy Compared to Androgen Deprivation Therapy Only for Metastatic Hormone‐sensitive Prostate Cancer." Cochrane Abstracts, John Wiley & Sons, Inc, 2025. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/431195/all/Abiraterone_acetate_in_combination_with_androgen_deprivation_therapy_compared_to_androgen_deprivation_therapy_only_for_metastatic_hormone‐sensitive_prostate_cancer.
Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone‐sensitive prostate cancer. Cochrane Abstracts. John Wiley & Sons, Inc; 2025. https://evidence.unboundmedicine.com/evidence/view/Cochrane/431195/all/Abiraterone_acetate_in_combination_with_androgen_deprivation_therapy_compared_to_androgen_deprivation_therapy_only_for_metastatic_hormone‐sensitive_prostate_cancer. Accessed March 15, 2025.
Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone‐sensitive prostate cancer. (2025). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/431195/all/Abiraterone_acetate_in_combination_with_androgen_deprivation_therapy_compared_to_androgen_deprivation_therapy_only_for_metastatic_hormone‐sensitive_prostate_cancer
Abiraterone Acetate in Combination With Androgen Deprivation Therapy Compared to Androgen Deprivation Therapy Only for Metastatic Hormone‐sensitive Prostate Cancer [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2025. [cited 2025 March 15]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/431195/all/Abiraterone_acetate_in_combination_with_androgen_deprivation_therapy_compared_to_androgen_deprivation_therapy_only_for_metastatic_hormone‐sensitive_prostate_cancer.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone‐sensitive prostate cancer
ID - 431195
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/431195/all/Abiraterone_acetate_in_combination_with_androgen_deprivation_therapy_compared_to_androgen_deprivation_therapy_only_for_metastatic_hormone‐sensitive_prostate_cancer
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
